Search filters

Filters
Clear All

Phase

  • 8
  • 10
  • 3
  • 2
  • 24
  • 13
  • 24

Found 24 Small Cell Lung Cancer trials

A listing of Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
The basic premise of this pilot study is to enroll 40 patients over 1.5 years who have Stage III or IV non-small cell lung cancer and are planned for definitive treatment with concurrent chemoradiation when a contrast-enhanced 4DCT is planned. The primary goal is to quantify the reproducibility of lung …
99 years or below
All genders
Phase 2
To evaluate the clinical activity (as assessed by objective response rate [ORR]) pembrolizumab (MK-3475) in combination with MK-4280 or lenvatinib in study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic treatment for their advanced disease.
 A Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
18 years - 99 years
All genders
Phase 2
Interventional
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-0482, MK-5890, MK-4830) in combination with pembrolizumab based therapy in patients with PD-(L)1 refractory NSCLC in a rolling-arm design
 S1900B A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
18 years - 99 years
All genders
Phase 2
This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
 A Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
18 years - 99 years
All genders
Phase 2
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-7684, MK-5890, MK-4830) in combination with pembrolizumab plus standard chemotherapy in treatment-naïve participants with advanced NSCLC.
 UPCC 16517: A Phase 1  First-in-Human  Open-Label  Dose Escalation Study of JNJ-61186372  a Human Bispecific EGFR and cMet Antibody  in Subjects with Advanced Non-Small Cell Lung Cancer
99 years or below
All genders
Phase 1
The purpose of this study is to see if JNJ-61186372 is safe and useful for treating patients with advanced, metastatic, non-small cell lung cancer (NSCLC).
 A  Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy  as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation- Positive  Locally Advanced or Metastatic Non-small Cell Lung Cancer
18 years - 99 years
All genders
Phase 3
Interventional
The purpose of this study is to try to find out if an experimental combination of an oral medication called osimertinib when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of non-small cell lung cancer (NSCLC). Eligible subjects will be adult subjects with …
 A pilot study to determine the feasibility of using plasma to detect mutations in patients with Stage II-III NSCLC
18 years - 99 years
All genders
This study will increase our ability to detect mutations in Stage II-III Non Small Cell Lung Cancer patients.
 UPCC 15518 / ANAM-17-21: A Phase 3  Randomized  Double-Blind  Placebo-Controlled  Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
18 years - 99 years
All genders
Phase 3
The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.
11 - 20 of 24